Clinical Trials Logo

Bladder Disease clinical trials

View clinical trials related to Bladder Disease.

Filter by:

NCT ID: NCT06395701 Recruiting - Bladder Cancer Clinical Trials

Trimodality Treatment in Bladder Cancer

Start date: April 1, 2014
Phase:
Study type: Observational

Bladder cancer is a malignant disease that affects a large number of people worldwide. An increase in the incidence of this type of cancer has been observed in recent decades, leading to a growing interest in understanding its risk factors, clinical evolution, and possible treatment approaches. This retrospective study aims to retrospectively analyze a cohort of patients diagnosed with muscle-invasive bladder cancer, in whom, after presentation at multidisciplinary oncology committees, the goal of curing the oncological disease while preserving the bladder is considered. Trimodal therapy (TMT) is the most studied bladder preservation strategy, with oncological outcomes superior to those of isolated therapies (or monotherapies) such as transurethral resection of the bladder tumor (TURBT), radiotherapy, or chemotherapy. TMT consists of complete and maximal TURBT of the bladder tumor, followed by definitive radiotherapy combined with a radiosensitizing agent. Objectives The main objective is to retrospectively analyze the effectiveness and safety of the trimodal approach in our setting. Collecting and analyzing data from patients treated in our service will provide valuable insight into clinical outcomes and treatment tolerability in this context. Materials and Methods - Study Design A retrospective study will be conducted using data from medical records of patients diagnosed with bladder cancer from 2014 to 2022 and treated with radiotherapy in our Radiation Oncology Service. Demographic data, medical history, risk factors, clinical characteristics, treatments received, and clinical outcomes will be collected. - Study Population The study population will include all patients with confirmed diagnoses of non-metastatic muscle-invasive bladder cancer.

NCT ID: NCT06337942 Recruiting - Bladder Cancer Clinical Trials

Deceased Donor Bladder or Combined Kidney-bladder Transplantation: a Phase 0 First-in-human Study

Start date: July 1, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to demonstrate the feasibility of bladder transplantation in patients with terminal bladder diseases who would benefit from a new bladder or a combined kidney and bladder transplant. The main questions it aims to answer are: - Is human bladder transplantation feasible and safe? - How will the new bladder function in terms of storage and emptying? Participants will undergo a bladder-only or combined kidney and bladder transplantation. They will then be followed for two years to evaluate the efficacy, safety, and functionality of the bladder transplant.

NCT ID: NCT06185218 Not yet recruiting - Bladder Disease Clinical Trials

Different Injection Site Maps & Intravesical Botulinum Toxin

Start date: April 2024
Phase: N/A
Study type: Interventional

Botulinum toxin injection into the bladder is used in current practice in urological diseases such as overactive bladder or interstitial cystitis. As far as is known, botulinum toxin injection sites have not been clearly defined. In this study, investigators are planning to compare botulinum toxin effectiveness with different injection site maps.

NCT ID: NCT06167356 Recruiting - Bladder Cancer Clinical Trials

Study on the Occurrence of Possible Relapses and on the Quality of Life in Patients Who Underwent TURBK.

Start date: November 27, 2013
Phase:
Study type: Observational

A database has been created and will be used in which data will be collected in electronic format relating to adult patients who underwent one of the following endoscopic resection surgeries: TURBK, MAPPING, TURBK SECOND LOOK, BLADDER BIOPSIES.

NCT ID: NCT05726786 Recruiting - Bladder Cancer Clinical Trials

The Role of Preoperative Immunonutrition on Morbidity and Immune Response After Cystectomy (INCyst Trial)

INCyst
Start date: April 10, 2023
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial research study is to evaluate the impact of preoperative oral immunonutrition (IN) on post-operative complications in patients undergoing a cystectomy. As a secondary focus, this study will aim to develop a signature that would identify patients that would benefit the most from IN. This is a multicentric (Swiss: N=3), prospective, controlled, pragmatic, parallel-group comparative study with block randomization stratified by centers.

NCT ID: NCT04200963 Completed - Neoplasms Clinical Trials

A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial Carcinoma

Start date: December 18, 2019
Phase: Phase 1
Study type: Interventional

This study will be conducted in adult subjects diagnosed with any form of an advanced or metastatic solid tumors including urothelial carcinoma for which standard therapy is no longer effective or is intolerable. This is a phase 1, multi-center, open label study designed to assess safety and tolerability of IK-175 as a single agent and in combination with nivolumab, to determine the recommended phase 2 dose (RP2D). Disease response, pharmacokinetics (PK), pharmacodynamics, and response biomarkers will also be assessed.

NCT ID: NCT04192474 Completed - Clinical trials for Lower Urinary Tract Symptoms

Evaluation of Performance and Safety of Ambu® aScope™ 4 Cysto and aView™ Urologia for Flexible Cystoscopy

Start date: July 21, 2020
Phase: N/A
Study type: Interventional

In this study, the new aScope 4 Cysto is used to see if this new single use, flexible cystoscope performs as well as other routinely used flexible cystoscopes. This study will be done in patients who come to the clinic for either a diagnosis of their urethra and bladder or for a small intervention. For an intervention a lesion or tumor is resected, a stent in the ureter is taken out, or an injection in the bladder wall is given. The flexible cystoscope is passed into the urethra and bladder for visual inspection of the bladder and urethra. It will give information on how well the structures of the urinary tract and bladder can be viewed including any abnormalities that are present. If an intervention is performed the aScope 4 Cysto will be used with an endoscopic accessory.

NCT ID: NCT04167631 Active, not recruiting - Bladder Cancer Clinical Trials

Can VI-RADS/ADC Accurately Stage Bladder Cancer??

Start date: January 1, 2019
Phase: N/A
Study type: Interventional

Vesical Imaging-Reporting And Data System (VI-RADS) is proposed for predicting muscle invasive bladder cancer (MIBC) using multi-parametric MRI. However, No validation study on VI-RADS has been reported yet. Apparent diffusion coefficient (ADC) values on diffusion-weighted MRI are reportedly significantly lower in MIBC than those in non-MIBC(NMIBC).

NCT ID: NCT04153227 Recruiting - Osteoporosis Clinical Trials

Osteoporosis, Trabecular Bone Score and Fracture Risk Assessment in Male Patients After Radical Cystectomy

Start date: May 1, 2018
Phase:
Study type: Observational [Patient Registry]

Radical cystectomy is associated with a greater risk of fracture due to long-term metabolic consequences of intestinal urinary diversions. One of the mechanisms theoretically involved with bone loss after radical cystectomy is metabolic acidosis that inhibits osteoblast activity, stimulates osteoclast bone resorption and urinary calcium loss. Other factors as advanced age, diabetes or chronic renal failure may increase the effect of metabolic acidosis. Moreover, osteoporosis in men remains under-diagnosed and under-appreciated. Although metabolic and bone changes after radical cystectomy are well known, bone mineral density (BMD) or fracture risk assessment are not recommended in different international guidelines during follow-up. The objective of this study is to evaluate the fracture risk of male patients undergoing radical cystectomy after more than one year of follow-up. Fracture risk assessment will be performed by BMD to analyse the prevalence of osteoporosis, vertebral fractures and measurement of Trabecular Bone Score (TBS) in combination with the Fracture Risk Assessment Tool (FRAX). These results will be correlated with blood markers with the objective to determine independent risk factors for osteoporosis or bone fracture in this population. To the best of the investigator's knowledge this will be the first study assessing the fracture risk after radical cystectomy performance evaluating BMD and the probability of fracture at 10 years using the FRAX algorithm.

NCT ID: NCT03591367 Completed - Bladder Cancer Clinical Trials

The Potential Role Of MicroRNA-155 And Telomerase Reverse Transcriptase In Diagnosis Of Non-Muscle Invasive Bladder Cancer And Their Pathological Correlation

Start date: August 1, 2018
Phase: N/A
Study type: Interventional

We try to assess the potential role of telomerase reverse transcriptase and MicroRNA (miR-155) in diagnosis of non-muscle-invasive bladder cancer and their correlation with stage and grade of the tumor.